A Review on Analysis of Flavonoid and Isoflavonoids Derivatives as Anticancer Agent using Swiss ADME

Zinney Moriju¹; Yugam Bansal²; Abhishek³; Wajid Shafi Beigh⁴; Jagroop Singh⁵; Poonam Bhauta^{6*} ^{1,2,3,4}Student, ⁵Assistant Professor, ^{6*}Associate Professor, Department of Pharmaceutical Chemistry, Sachdeva College of Pharmacy, Gharuan.

Abstract:- Cancer, generally characterized by uncontrollable growth of abnormal cells that metastasize to other parts of the body. It is a one of the leading concerned disease that affects the worldwide population. It can originate from almost any organ or tissue and are of various types; leukemia, lung cancer, lymphoma, stomach cancer, cervical cancer.

Flavonoids and Isoflavonoids are naturally occurring polyphenolic secondary metabolites that numerous medicinal benefits possess including antioxidant, anti-inflammatory, anticancer and antiviral properties. Potential agents derived from flavonoids and isoflavonoids for its anticancer activity have been studied. Due to recent technological advancement, the detailed study of any moiety and molecules is possible. A virtual screening of flavonoids was carried out using molecular docking, drug similarity, ADMET prediction, drug likeness, chemical and physicochemical properties to determine its potential anticancer activity with the use of Swiss ADME and Chem Draw software.

In this review, analysis of drug likeness properties of flavonoids and isoflavonoids was thoroughly performed. Additionally, structures were examined and observed for better interaction of flavonoids scaffold with receptors. Due to their great stability, flavonoids are strongly recommended as anticancer medicines for various cancer stages.

I. INTRODUCTION

> Cancer

Cancer is a broad family of illnesses arising from uncontrolled division of abnormal cells that metastasize to other parts of the body. These problems can originate in almost any organ ortissue within the human system. The latter is known as metastasizing and has a significantrole in cancerrelated deaths. Malignant tumour and neoplasm are other names for cancer^{1,2}. Furthermore, a mutation in the p53 gene results in the production of a unique protein that modifies the molecular mechanisms associated with p53. There is a complicated relationship between the p53 gene and cancer; studies have demonstrated thatp53 aberration accounts for 60% of cancer cases. Cancer cells are produced as a result of these genetic and biological processes going away. Under normal circumstances, P53 is essential for angiogenesis, differentiation, senescence, cell death, cell division, and DNA metabolism. Furthermore, the DNA-binding area is impacted by most p53 gene mutations, and p53 controls the capacity of genes to replicate. Cancer cells associate with CDK1-P2 and CDC2. through p53, which keep them in the first and second growth phases of the cell cycle. (3,4)




Fig 1: U.S. FDA Approved Anti-Cancer Drugs from Year 2016 -2024




Fig 2: Types of Cancer

II. FLAVONES AS ANTICANCER AGENTS

Plants and 26 different foods include a class of secondary polyphenol metabolites called flavonoids. Numerous bioactive qualities are believed to be present in them, such as anti-cancer, antiviral, anti-inflammatory, anti-diabetic, cardioprotective, and anti-aging effects. Their fundamental structures of C6-C3-C6 rings(6).

A. SAR of Flavonoids for Anti-Cancer Activity

One family of flavonoids consists of the two main types: isoflavonoids, the first having a C6-C3-C6 structure, and flavonoids (in the strict sense). The significance of flavonoids in cancer therapy has been shown by a number of processes, such as the induction of programmed cell death, nuclear signalling inhibition, proteasome inhibition, factor differentiation induction, and initiation of cell cycle arrest. Many studies have been conducted on flavonoid-based cytostatic anti-cancer medicines because they may exhibit selective cytotoxicity on cancer cells. Double bonds between C2 and C3 are essential for planarity and molecular conjugation. Certain hydroxylated flavonoids between rings C and A/B have more inhibitory effects on cancer cells for effective carcinoma inhibition. Ring B's additional hydroxyl group alteration has no effect on the activity. It has been proposed to substitute ring B with a catechol moiety, which has significant ramification. In ring C, Figure 3 illustrates that 3-hydroxylation has been identified as a highly significant moiety for increasing biological action. Biological activity is enhanced by derivatives having ortho methylation substitution on flavanoids, which are generally associated with ring A polymethoxylation.(7)

B. Scaffold-hopping of Bioactive Flavones

Scaffold-hopping of bioactive template/drug is an important strategy in drug design to produce distinct molecules with desired properties. Lead hopping, often known as scaffold hopping, is a strategy for discovering structurally novel molecules. The finding of iso-functional molecular structures that, critically, contain several molecular backbones is referred to as "scaffold-hopping". By emphasising the degree of alteration relative to the original parent molecules, the classification of scaffold hopping techniques helps to rationalize the idea of scaffold hopping. A 1° hop is a little modification in which heteroatoms and carbon in a backbone ring are switched or replaced more extensive ring openings and closures are indicative of a 2° hop. A 3° hop occurs when the peptide backbone is replaced with non-peptic molecules. Finally, a completely new chemical structure that just maintains connections is referred to as a 4° hop. a technique that finds potent anticancer medications by jumping from one scaffold to another utilising bioactive natural chemicals like isoflavones and flavones(8)

III. IMPORTANCE OF FLAVANOID AND ISOFLAVANOID DERIVATIVES

Within the plant kingdom, flavonoids are a group of naturally occurring 2° plant polyphenolic metabolites that are extensively dispersed and, as a result, often found in diets. Typically, they are identified as compounds whose principal structure is the 15-carbon having C6-C3-C6 carbon nucleus. A heterocyclic ring, two phenyl rings (A and B), and two phenyl rings make up these oen. Biological studies on natural and synthetic flavonoid analogues have revealed a variety of bioactivities exhibited by these species, including anxiolytic, anti-microbial, anti-cancer, anti-inflammatory, anti-ulcer, and anti-thrombosis properties(9)

ISSN No:-2456-2165

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

IV. CHEMICAL PROPERTIES OF FLAVONOIDS

The phenylpropanoid chain containing 15-carbon (C_6 - C_3C_6) which is made up of two aromatic rings (A and B) joined by a heterocyclic pyran ring (C) is the fundamental

flavan skeleton shared by all flavonoids (Figure 3). Flavonoids might be further classified into six main classes based on their chemical structure, degree of oxidation, and unsaturation in connecting chain, which are: isoflavonoids, flavanones, flavanols, flavones, and anthocyanidins.




Fig 3: Different Structural Examples of Flavonoids

▶ In Flavonoids or Isoflavonoids, a Chromane Ring (A and C) is Joined to a B Ring (Figure 3) at C2 or C3.




Fig 4: Structural Examples of the Main Isoflavonoids

Volume 9, Issue 4, April – 2024 ISSN No:-2456-2165

> Flavanones, also Known as di-Hydroflavones, have Oxidised and Saturated, C Ring.




Fig 5: Chemical Structures of Main Flavanones

The C ring of flavanols is saturated, unoxidized, and has a hydroxyl group at position C_3 . The most common stereoisomers of catechins are trans ((+) catechin or cis ((-)epicatechin), depending on where C_2 and C_3 are located in the

molecule. Epicatechin gallate, epigallocatechin, and epigallocatechin gallate are gallic acid conjugates that flavanols can produce during esterification with gallate groups.




Fig 6: Chemical Structures of Main Flavanols

Flavonols have an unsaturated C ring at position C_2 - C_3 , which is usually oxidized at C_4 and hydroxylated at C_3 . Kaempferol and quercetin are the main flavonols; myricetin,

isorhamnetin, fisetin, and galangin are present in lesser amounts (Figure 7). The –OH moieties of flavonols are responsible for their biological effects.




Fig 7: Chemical Structures of Main Flavonols

Flavones have no hydroxy group at C_3 , and ring C is unsaturated at positions C_2 - C_3 , with ketonic group at position

 $C_4(10)$. Apigenin, luteolin, chrysin, and tangeritin are the primary flavones (Figure 8).




Fig 8: Chemical Structures of Main Flavones

ISSN No:-2456-2165

Anthocyanidins are pH-dependent pigments obtained from plant which are water-soluble, unsaturated, and unoxidized flavonoids. The fundamental structure of the phenylbenzopyrylium chromophore–flavylium ion serves as the basis for anthocyanidins. In anthocyanidins the ring B is hydroxylated at the C_3 position (11). (Figure 9) The principal anthocyanidins include cyanidin, pelargonidin, peonidin, petunidin, delphinidin and malvidin.

https://doi.org/10.38124/ijisrt/IJISRT24APR2622




Fig 9: Structural Examples of Main Anthocyanidins

There are two forms of flavonoids: aglycones without connected sugars and glycosides with linked sugars(11, 12). Flavonoids combine to create phenolate anions and neutral phenols in the cytosol (pH 7.4). The pKa of every phenolic group determines their relative amounts. Given that flavonoids are weak hydrophobic acids, their ability to traverse cellular and mitochondrial membranes will depend on how lipophilic they are.

V. ANTICANCER EFFECTS OF FLAVONOIDS

Flavonoids may clean the free radicals, regulate cellular metabolism, and prevent diseases linked to oxidative stress, according to a number of studies. Many flavonoids have been shown to have anticancer activities by an increasing amount of research; however, the precise molecular processes underlying these actions are yet understood. Cancer is a multifaceted disease characterised by the growth of abberant cells that invade and spread to different areas of the body as a result of uncontrolled proliferation and a disturbed cell cycle. The main internal causes of cancer are Oxidative stress, hypoxia, genetic modifications, and loss of apoptotic function. The main external causes are elevated stress, pollution, smoking, radiation, and UV radiation exposure.(2)

Changes in metabolism, disturbed cell cycles, immunological response resistance, recurrent mutations, chronic inflammation, metastasis formation, and angiogenesis stimulation are the main features of cancer cells. A increasing body of research suggests that cancer is a metabolic disease caused by varied degrees of mitochondrial malfunction and metabolic abnormalities. The main metabolic changes in the cancer cells include increased aerobic glycolysis, acidosis, decreased lipid metabolism , increased ROS generation , and decreased enzyme activity(13)

This directly causes hyperpolarized mitochondria, decreased membrane cardiolipin levels that impair enzyme activities, increased glutamine-driven lipid biosynthesis that upregulates the pathways involved in the initiation and metastasis of tumours, an acidic extracellular environment that is more conducive to inflammation, and an effect that is correlated with the invasiveness and malignancy of cancer cells. Flavonoids have different types of anticancer properties, such as regulating the activities of enzymes that clean the reactive oxygen species, arresting the cell cycle, trigger the programmed cell death, autophagy, and reducing the growth and invasiveness of cancer cells.(2, 14)

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

VI. ANALYSIS OF DRUG LIKENESS PROPERTIES FOR FLAVANOIDS AND ISOFLAVANOIDS USING SWISSADME SOFTWARE

We looked at the drug-like properties of several flavones and isoflavones derivatives in the study to ascertain the superior physiochemical properties of the basic moiety with a wide range of substitution on the flavones and isoflavones scaffold. To identify the possible flavanoids structure against CDK8, a virtual screening of flavanoids was performed utilising molecular docking, drug similarity, ADMET prediction, and a molecular dynamics MD simulation technique. Since flavonoids are naturally occurring substances that have been a part of human diet and drink since ancient times, they do not have the same aftereffects as manmade anticancer medications.

Several studies have shown their significant beneficial effects on the response of the immune system, the reduction of inflammation, and the maintenance and restoration of normal cellular functions. Because of their broad variety of anticancer actions, flavanoids may provide useful resources for future studies into the creation of novel cancer chemopreventive drugs and the subtleties of their modes of action.

Molecule 1			
H000			Water Solubility
	LIPO	Log S (ESOL)	-4.09
		Solubility	1.80e-02 mg/ml ; 8.11e-05 mol/l
Î	FLEX SIZE	Class 0	Moderately soluble
\sim		Log S (All) 🧐	-3.88
		Solubility	2.93e-02 mg/ml ; 1.32e-04 mol/l
A Cont		Class 0	Soluble
	BISATU FOLAR	Log S (SILICOS-IT) 0	-6.13
\sim		Solubility	1.63e-04 mg/mi ; 7.33e-07 mol/l
		Class 0	Poorly soluble
	MSOLU		Pharmacokinetics
SMILES O=ctcc(oc2ctco	002)01000001	GE absorption 🥹	High
II PI	hysicochemical Properties	BBB permeant 0	Yes
Formula	C15H10O2	P-gp substrate 0	No
Molecular weigt	222 24 g/mol	CYP1A2 inhibitor 😣	Yes
Num beavy atoms	JE .	CYP2C19 inhibitor 9	Yes
Nam arout heavy alorns	✓16	CYP2C9 inhibitor 9	No
Faction Chp3	0.00	CYP2D6 inhibitor 0	No
Nunt votatable bonds	1	CYP3A4 inhibitor 0	No
Num. H-bond acceptors	2	Log K ₂ (skin permeation)	-5.13 cm/s
Num. H-bond donors	0		Druglikeness
Molar Refractivity	67.92	Lipinski 🕕	Yes; 0 violation
TPSA 0	30.21 Å*	Ghose 😑	Yes
	Lipophilicity	Veber 😣	Yes
Log Pow (ILOGP) 😐	2.55	Egan 😣	Yes
Log Pow (XLOGP3) 😣	3.56	Muegge O	Yes
Log Pow (WLOGP) 🤒	3.46	Bioavailability Score 9	0.55
Log P _{s/w} (MLOGP) 10	2.27		Medicinal Chemistry
Log Pew (SILICOS-IT) 🌖	4.04	PAINS 0	0 alert
Consensus Log P _{siw} 🔍	3.18	Brenk 🥹	0 alert
		Leadlikeness 0	No: 2 violations: MW<250, XLOGP3>3.5
		Synthetic accessibility 0	2.88

Fig 10: Analysis of Drug Likeness of Molecule 1

www.ijisrt.com

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

000			Water Solubility
	LIPO	Log S (ESOL) 🥹	-3.85
		Solubility	3.13e-02 mg/mi ; 1.41e-04 mol/l
\land	FLEX	Class 0	Soluble
í í í		Log S (Ali) 🥯	-3.49
		Solubility	7.27e-02 mg/ml ; 3.27e-04 mol/l
× ĭ ĭ		Class 🐵	Soluble
Ľ, Ľ	POLAR	Log S (SILICOS-IT) 0	-6.13
0	POLAR	Solubility	1.63e-04 mg/ml ; 7.33e-07 mol/l
		Class 🥯	Poorly soluble
	INSOLU		Pharmacokinetics
	-21-44	GI absorption 🥯	High
SMILES O=c1c(coc2c1ccc		BBB permeant 😣	Yes
Formula	vsicochemical Properties C15H10O2	P-gp substrate 🛞	No
Molecular weight	222.24 g/mol	CYP1A2 inhibitor 🥯	Yes
Num, heavy atoms	17	CYP2C19 inhibitor 9	Yes
Num. arom. heavy atoms	16	CYP2C9 inhibitor 69	No
Fraction Csp3	0.00	CYP2D6 inhibitor 🥯	No
Num. rotatable bonds	1	CYP3A4 inhibitor 🥯	No
Num. H-bond acceptors	2	Log K _n (skin permeation) 🥯	-5.40 cm/s
Num. H-bond donors	0	- p	Druglikeness
Molar Refractivity	67.92	Lipinski 🛞	Yes: 0 violation
TPSA 😣	30.21 Å ²	Ghose 😣	Yes
	Lipophilicity	Veber 😣	Yes
Log P _{o/w} (iLOGP) 😣	2.51	Egan 😣	Yes
Log P _{o/w} (XLOGP3) Θ	3.18	Muegge 🥹	Yes
Log P _{o/w} (WLOGP)	3.46	Bioavailability Score 😡	0.55
Log P _{o/w} (MLOGP) 🥹	2.27		Medicinal Chemistry
Log P _{o/w} (SILICOS-IT)	4.04	PAINS 9	0 alert
Consensus Log Poly	3.09	Brenk 🥯	0 alert
o onio colgi r o/w	0.00	Leadlikeness 🥯	No; 1 violation: MW<250
		Synthetic accessibility 🥯	2.82

Fig 11: Analysis of Drug Likeness Property of Molecule 2

Nolecule 3			
000			Water Solubility
	LIPO	Log S (ESOL)	-4.13
		Solubility	1.76e-02 mg/ml ; 7.47e-05 mol/l
	FLEX	Class 💿	Moderately soluble
*		Log S (Ali) 😡	-3.86
		Solubility	3.27e-02 mg/ml; 1.38e-04 mol/l
$\sim \gamma \gamma$		Class 😔	Soluble
0	POLAR	Log S (SILICOS-IT) 😣	-6.52
	PUCAR	Solubility	7.10e-05 mg/ml; 3.01e-07 mol/l
		Class 🛞	Poorly soluble
	INSOLU		Pharmacokinetics
MILES Cc1ccc(cc1)c1co	20(01-0)00002	GI absorption 📀	High
	vsicochemical Properties	BBB permeant 😣	Yes
ormula	C16H12O2	P-gp substrate 🥯	No
lolecular weight	236.27 g/mol	CYP1A2 inhibitor 🔞	Yes
um, heavy atoms	18	CYP2C19 inhibitor 😔	Yes
um. arom. heavy atoms	16	CYP2C9 inhibitor 9	No
raction Csp3	0.06	CYP2D6 inhibitor 9	No
um, rotatable bonds	1	CYP3A4 inhibitor 🗐	No
um. H-bond acceptors	2	Log K _n (skin permeation) 9	-5.23 cm/s
lum. H-bond donors	0	Log / p (our pornounon)	Druglikeness
Iolar Refractivity	72.89	Lipinski 🥹	Yes: 0 violation
PSA 😕	30.21 Ų	Ghose 0	Yes
	Lipophilicity	Veber 🔍	Yes
.og P _{o/w} (iLOGP) 🥹	2.75	Egan 😣	Yes
.og P _{o/w} (XLOGP3) 🥯	3.54	Muegge 💿	Yes
.og P _{o/w} (WLOGP) 🥯	3.77	Bioavailability Score 🥯	0.55
og P _{o/w} (MLOGP) 😣	2.52		Medicinal Chemistry
.og Poly (SILICOS-IT) 💿	4.51	PAINS	0 alert
Consensus Log Poly 0	3.42	Brenk 🗐	0 alert
	- J . T 2	Leadlikeness 🥯	No; 2 violations: MW<250, XLOGP3>3.5
		Synthetic accessibility 🥯	2.91

Fig 12: Analysis of Drug Likeness of Substituted Molecule 3

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

Molecule 4			
000			Water Solubility
	LIPO	Log S (ESOL) 🥯	-4.42
		Solubility	9.68e-03 mg/ml ; 3.77e-05 mol/l
	FLEX	Class 🍩	Moderately soluble
		Log S (Ali) 🗐	-4.14
	\sim	Solubility	1.86e-02 mg/ml ; 7.26e-05 mol/l
$\sim \gamma \gamma$		Class 🍩	Moderately soluble
	POLAR	Log S (SILICOS-IT) 0	-6.75
	INSATU POLAR	Solubility	4.59e-05 mg/ml ; 1.79e-07 mol/l
		Class 🐵	Poorly soluble
	INSOLU		Pharmacokinetics
		GI absorption 😡	High
SMILES Clc1ccc(cc1)c1co		BBB permeant 9	Yes
	nysicochemical Properties	P-gp substrate 💿	No
Formula Aolecular weight	C15H9ClO2	CYP1A2 inhibitor 🥯	Yes
lum, heavy atoms	256.68 g/mol 18	CYP2C19 inhibitor 🥯	Yes
vum, neavy atoms vum, arom, heavy atoms	16	CYP2C9 inhibitor 9	No
Fraction Csp3	0.00	CYP2D6 inhibitor 😣	No
lum, rotatable bonds	1	CYP3A4 inhibitor 🥯	No
lum. H-bond acceptors	2	Log K _n (skin permeation) 🥯	-5.16 cm/s
lum. H-bond donors	0		Druglikeness
Molar Refractivity	72.93	Lipinski 🥹	Yes; 0 violation
TPSA 😣	30.21 Ų	Ghose 😣	Yes
	Lipophilicity	Veber 😳	Yes
.og P _{o/w} (iLOGP) 🥯	2.79	Egan 🛞	Yes
Log P _{o/w} (XLOGP3) 🐵	3.81	Muegge 😣	Yes
Log P _{o/w} (WLOGP) 😣	4.11	Bioavailability Score 😡	0.55
Log P _{o/w} (MLOGP) 😣	2.79		Medicinal Chemistry
Log Poly (SILICOS-IT)	4.64	PAINS 😔	0 alert
		Brenk 🥯	0 alert
Consensus Log P _{olw} 😣	3.63	Leadlikeness 💿	No; 1 violation: XLOGP3>3.5
		Synthetic accessibility 🥯	2.77



Molecule 5			
000			Water Solubility
	LIPO	Log S (ESOL) 🥯	-3.92
		Solubility	2.83e-02 mg/ml ; 1.19e-04 mol/l
HO	FLEX	Class 0	Soluble
		Log S (Ali) 🧐	-3.93
		Solubility	2.79e-02 mg/ml ; 1.17e-04 mol/l
L L		Class 🛞	Soluble
Y	INSATU POLAR	Log S (SILICOS-IT) 😣	-5.56
0	PULAR	Solubility	6.56e-04 mg/ml ; 2.75e-06 mol/l
		Class 🥯	Moderately soluble
	INSOLU		Pharmacokinetics
	0.000	GI absorption 🧐	High
SMILES Oc1ccc(cc1)c1cc		BBB permeant 🥯	Yes
Formula	nysicochemical Properties C15H10O3	P-gp substrate 💿	No
Volecular weight	238.24 g/mol	CYP1A2 inhibitor 🥯	Yes
Num. heavy atoms	236.24 g/moi 18	CYP2C19 inhibitor 🥯	Yes
Num. arom. heavy atoms	16	CYP2C9 inhibitor 🥯	No
Fraction Csp3	0.00	CYP2D6 inhibitor 🥯	Yes
Num. rotatable bonds	1	CYP3A4 inhibitor 🗐	Yes
Num. H-bond acceptors	3	Log K_p (skin permeation) 0	-5.48 cm/s
Num. H-bond donors	1		Druglikeness
Molar Refractivity	69.94	Lipinski 🥯	Yes; 0 violation
TPSA 🥯	50.44 Ų	Ghose (9)	Yes
	Lipophilicity	Veber 🥯	Yes
Log P _{o/w} (iLOGP) 😣	2.20	Egan 😣	Yes
Log P _{o/w} (XLOGP3) 😡	3.20	Muegge 🥯	Yes
Log P _{o/w} (WLOGP) 😣	3.17	Bioavailability Score	0.55
Log P _{o/w} (MLOGP) 🥯	1.66		Medicinal Chemistry
Log P _{olw} (SILICOS-IT) 🥯	3.52	PAINS	0 alert
Consensus Log Pow 0	2.75	Brenk 🥯	0 alert
0/W		Leadlikeness 🥺	No; 1 violation: MW<250
		Synthetic accessibility 🥯	2.74

Fig 14. Analysis of drug likeness property 5

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

Nolecule 6			
000			Water Solubility
	LIPO	Log S (ESOL) 🗐	-4.66
		Solubility	5.66e-03 mg/ml ; 2.20e-05 mol/l
	FLEX	Class 🧐	Moderately soluble
		Log S (Ali) 😑	-4.52
		Solubility	7.69e-03 mg/ml ; 3.00e-05 mol/l
		Class 🧐	Moderately soluble
\mathbf{Y}	POLAR	Log S (SILICOS-IT) 🥯	-6.75
0	INSATU POLAR	Solubility	4.59e-05 mg/ml ; 1.79e-07 mol/l
		Class 🥹	Poorly soluble
	INSOLU		Pharmacokinetics
		GI absorption 🤨	High
MILES Clc1ccc(cc1)c1cc		BBB permeant 😣	Yes
Formula	nysicochemical Properties C15H9ClO2	P-gp substrate 😣	No
Volecular weight		CYP1A2 inhibitor <	Yes
_	256.68 g/mol	CYP2C19 inhibitor 🗐	Yes
lum. heavy atoms lum. arom. heavy atoms	18	CYP2C9 inhibitor	Ne
raction Csp3	0.00	CYP2D6 inhibitor 0	No
lum, rotatable bonds	1	CYP3A4 inhibitor 9	Ne
lum. H-bond acceptors	2		-4.90 cm/s
lum. H-bond donors	0	Log K _p (skin permeation) 😣	
Iolar Refractivity	72.93		Druglikeness
PSA 9	30.21 Å ^z	Lipinski 😡	Yes; 0 violation
	Lipophilicity	Ghose 🧐	Yes
.og P _{o/w} (iLOGP) 🔞	2.81	Veber 9	Yes
10		Egan 🥯	Yes
og P _{olw} (XLOGP3) 😡	4.18	Muegge 🛞	Yes
.og P _{o/w} (WLOGP) 🥯	4.11	Bioavailability Score 🥯	0.55
.og P _{o/w} (MLOGP) 🥯	2.79	2	Medicinal Chemistry
og P _{o/w} (SILICOS-IT) 🥯	4.64	PAINS 📀	0 alert
Consensus Log Poly 0	3.71	Brenk 🥯	0 alert
Jonsensus Log Poly	5.74	Leadlikeness 🥯	No; 1 violation: XLOGP3>3.5
		Synthetic accessibility 🥯	2.84

Fig 15: Analysis of Drug Likeness Property of Molecule 6




Fig 16: Analysis of Drug Likeness Property of Molecule 7

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

Molecule 8			
000			Water Solubility
	LIPO	Log S (ESOL) 🥹	-4.09
		Solubility	1.80e-02 mg/ml ; 8.11e-05 mol/l
	FLEX SIZE	Class 🥯	Moderately soluble
	\sim	Log S (Ali) 😣	-3.88
		Solubility	2.93e-02 mg/ml ; 1.32e-04 mol/l
Ľ L		Class 🥯	Soluble
Ύ ·	INSATU POLAR	Log S (SILICOS-IT)	-6.13
0		Solubility	1.63e-04 mg/ml ; 7.33e-07 mol/l
		Class 🥹	Poorly soluble
	INSOLU		Pharmacokinetics
SMILES O=c1cc(oc2c1cc	c2)c1ccccc1	GI absorption @	High
	vsicochemical Properties	BBB permeant 🥯	Yes
Formula	C15H10O2	P-gp substrate 🥯	No
Molecular weight	222.24 g/mol	CYP1A2 inhibitor 🥹	Yes
Num. heavy atoms	17	CYP2C19 inhibitor 😣	Yes
Num. arom. heavy atoms	16	CYP2C9 inhibitor 🧐	No
Fraction Csp3	0.00	CYP2D6 inhibitor 🥯	No
Num. rotatable bonds	1	CYP3A4 inhibitor 🥯	No
Num. H-bond acceptors	2	Log K _p (skin permeation)	-5.13 cm/s
Num. H-bond donors	0		Druglikeness
Molar Refractivity	67.92	Lipinski 🥯	Yes: 0 violation
TPSA 🧐	30.21 Ų	Ghose ()	Yes
	Lipophilicity	Veber 🥹	Yes
Log P _{o/w} (iLOGP) 🥯	2.55	Egan 🐵	Yes
Log P _{o/w} (XLOGP3) 🥯	3.56	Muegge 💿	Yes
.og P _{o/w} (WLOGP) 🧐	3.46	Bioavailability Score (9)	0.55
.og P _{o/w} (MLOGP) Օ	2.27		Medicinal Chemistry
Log P _{o/w} (SILICOS-IT) 🥯	4.04	PAINS 🥹	0 alert
Consensus Log Po/w	3.18	Brenk 🥯	0 alert
5 011		Leadlikeness 🥯	No; 2 violations: MW<250, XLOGP3>3.5
		Synthetic accessibility 0	2.88

Fig 17: Analysis of Drug Likeness Property of Molecule 8

Molecule 1			
👬 🔁 🔿 🄗			Water Solubility
	LIPO	Log S (ESOL) 🥹	-3.74
		Solubility	4.11e-02 mg/ml ; 1.83e-04 mol/l
	FLEX	Class 📀	Soluble
		Log S (Ali) 🥹	-3.21
	=	Solubility	1.39e-01 mg/ml ; 6.20e-04 mol/l
		Class 📀	Soluble
	INSATU	Log S (SILICOS-IT) 📀	-4.76
		Solubility	3.86e-03 mg/ml ; 1.72e-05 mol/l
		Class 🔞	Moderately soluble
	INSOLU		Pharmacokinetics
SMILES c1ccc2c(c1)C1Oc	3c(C1CO2)cccc3	GI absorption 📀	High
	ysicochemical Properties	BBB permeant 🥹	Yes
Formula	C15H12O2	P-gp substrate 📀	Yes
Molecular weight	224.25 g/mol	CYP1A2 inhibitor 📀	Yes
Num. heavy atoms	17	CYP2C19 inhibitor 🧐	No
Num. arom. heavy atoms	12	CYP2C9 inhibitor 🧐	No
Fraction Csp3	0.20	CYP2D6 inhibitor 📀	Yes
Num. rotatable bonds	0	CYP3A4 inhibitor 📀	No
Num. H-bond acceptors	2	Log K _p (skin permeation) 📀	-5.43 cm/s
Num. H-bond donors	0	P.	Druglikeness
Molar Refractivity	64.65	Lipinski 📀	Yes; 0 violation
TPSA 🔞	18.46 Ų	Ghose 📀	Yes
	Lipophilicity	Veber 🧐	Yes
Log P _{o/w} (iLOGP) 😣	2.51	Egan 📀	Yes
Log P _{o/w} (XLOGP3) 📀	3.15	Muegge 📀	Yes
Log P _{o/w} (WLOGP) 📀	2.97	Bioavailability Score 📀	0.55
Log P _{o/w} (MLOGP) 😣	2.81		Medicinal Chemistry
Log P _{o/w} (SILICOS-IT) 📀	3.28	PAINS 0	0 alert
Consensus Log P _{o/w} 😣	2.95	Brenk 🥹	0 alert
5 UW		Leadlikeness 📀	No; 1 violation: MW<250
		Synthetic accessibility 📀	3.29

Fig 18. Analysis of Drug Likeness Property of Molecule 9

ISSN No:-2456-2165

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

A. Apigenin

Several studies have demonstrated their very positive benefits on the immune system's response, the reduction of inflammation, and the maintenance and restoration of normal cellular functions. Because flavanoids have a broad spectrum of anticancer characteristics, they can provide important information for future research on the subtleties of the mechanisms of action of novel cancer chemopreventive drugs.(15)

Apigenin is a small molecular weight compound that structurally produces pure yellow needles (mw = 270.24). With a melting point of 347.5, apigenin is soluble in DMSO and diluted KOH but insoluble in water. It also dissolves somewhat in heated alcohol. Using it with strong oxidising chemicals is not recommended. It is recommended to store pure apigenin at -20°C due to its high instability.(16) According to the single-pass intestinal perfusion method, it has a good intestinal permeability but a poor solubility in the aqueous phase. This flavone inhibit the growth of cancer cells by causing autophagy, initiating cell apoptosis, and altering the cell cycle. Moreover, apigenin prevents the migration and invasion of cancer cells as well as their motility. Apigenin has been shown to exhibit anti-cancer properties via inducing an immunological response.(17) In its chemical structure, apigenin has three H-bond donors and five H-bond acceptors. Its log P value of 1.91 indicates that it is suitable for oral formulations and does not break any Lipinski restrictions. It was discovered to have no BBB penetration and strong G.I. absorption. Through inducing cell cycle arrest at the G2/M phase, it has been found to possess antiproliferative action against human colon carcinoma and breast cancer cell lines.3. Hesperidin and apigenin exhibit minimal toxicity and strong cytotoxic effects on the MCF7 cell line, with an IC50 of 10 $\mu g/ml..(18)$

Molecule 1			
Ħ 🛛 📿 🏈			Water Solubility
	LIPO	Log S (ESOL) 🤨	-3.72
		Solubility	5.11e-02 mg/ml; 1.89e-04 mol/l
	FLEX	Class 📀	Soluble
	ОН	Log S (Ali) 🔞	-4.23
		Solubility	1.59e-02 mg/ml ; 5.88e-05 mol/l
		Class 0	Moderately soluble
но он			-4.40
	INSATU	Log S (SILICOS-IT) 🕗 Solubility	-4.40 1.07e-02 mg/ml ; 3.94e-05 mol/l
		Class 🥹	Moderately soluble
	INSOLU	01033 🤝	Pharmacokinetics
04450 0-4(1) 1	-0-(-1-0)-(-0)(-0)0	GI absorption 📀	High
SMILES Oc1ccc(cc1)c1coc		BBB permeant	No
Formula	vsicochemical Properties C15H10O5	P-gp substrate 0	No
Molecular weight	270.24 g/mol	CYP1A2 inhibitor ⁽³⁾	Yes
Num. heavy atoms	20	CYP2C19 inhibitor 📀	No
Num. arom. heavy atoms	16	CYP2C9 inhibitor ⁽³⁾	No
Fraction Csp3	0.00	CYP2D6 inhibitor 🧐	Yes
Num. rotatable bonds	1	CYP3A4 inhibitor 📀	Yes
Num. H-bond acceptors	5	Log Kp (skin permeation) 📀	-6.05 cm/s
Num. H-bond donors	3	F	Druglikeness
Molar Refractivity	73.99	Lipinski 📀	Yes; 0 violation
TPSA 📀	90.90 Ų	Ghose 📀	Yes
	Lipophilicity	Veber 🤫	Yes
Log P _{o/w} (iLOGP) 🛞	1.91	Egan 🔞	Yes
Log P _{o/w} (XLOGP3) 📀	2.67	Muegge 📀	Yes
Log P _{o/w} (WLOGP) 📀	2.58	Bioavailability Score 🧐	0.55
Log P _{o/w} (MLOGP) 🤨	0.52		Medicinal Chemistry
Log Poly (SILICOS-IT)	2.52	PAINS 🧐	0 alert
Consensus Log P _{o/w} ⁽⁹⁾	2.04	Brenk 📀	0 alert
Conscious Log F 0/W	2.04	Leadlikeness 📀	Yes
		Synthetic accessibility 📀	2.87

Fig 19: Analysis of Drug Likeness Property of Molecule 10

B. Genistein

People in Asian nations commonly consume soy and soy-based food items, which include genistein [5,7-dihyroxy-3-(-4-hydroxyphenyl)-4H-1-benzopyran-4-one]. Numerous epidemiological studies have revealed that Asian nations had lower rates of some cancer kinds than Western nations, including prostate and breast cancer. As a result, there has been a growing focus on the potential role that a rich isoflavone diet may have in both preventing and suppressing the development of tumours.(19) Genistein and oestrogen share a very similar structural makeup. Isoflavones have so been referred to as phytoestrogens.

ISSN No:-2456-2165

Due to structural resemblance, genistein may attach itself to oestrogen receptors. By doing so, it influences the cell signal transduction system and controls the components involved in cell signalling. As a result, it has a broad range of biological functions, but its capacity to stop the spread of cancer is what makes it most famous.(20) Soybeans contain genistein, a naturally occurring isoflavone phytochemical. People having high intake of soy in their diet also excrete urine which contains free genistein and other linked isoflavones that are available in circulating blood, accumulate in tissue, and are converted by the natural gut microflora from the glucoside conjugates of soy in the gastrointestinal tract. Genistein's antiproliferative action has also been linked to the induction of apoptosis(21) and the direct inhibition of topoisomerase-II 34. The control of cytokine generation inhibits the growth of ovarian cancer cells. It has been found that genistein prevents the growth of ovarian cancer cells by influencing the cytokine IL-6, which impacts immunological homeostasis and inflammatory responses (22). An isoflavonoid called genistein controls the course of the cell cycle, programmed cell death, and metastasis. Genistein was shown to be a particular inhibitor of receptor tyrosine kinase (RTK), which includes EGFR(23), in 1987. Genistein is just as successful as its mother cell line in inducing differentiation in a multi-drug resistant K562 (human myelogenous leukaemia) cell line. It claims that soy contains the potent anti-cancer chemicals genistein and daidzein, which are isoflavones. With a molecular weight of only 270.24 g/mol, genistein is a lipophilic molecule containing 20 heavy atoms and 16 aromatic heavy atoms, respectively. It lacks BBB penetrating properties and has a high G.I. absorption rate. It has three H-bond donors and five H-bond acceptors. In cold water, genistein is insoluble; in hot water and other solvents, it is somewhat soluble.

Molecule 1			
ii 🛛 🖓 🄗			Water Solubility
	LIPO	Log S (ESOL) 📀	-3.94
		Solubility	3.07e-02 mg/ml ; 1.14e-04 mol/l
0 0H	FLEX SIZE	Class 📀	Soluble
		Log S (Ali) 😣	-4.59
Í Ť		Solubility	6.88e-03 mg/ml ; 2.55e-05 mol/l
	ОН	Class 📀	Moderately soluble
	INSATU	Log S (SILICOS-IT) 📀	-4.40
		Solubility	1.07e-02 mg/ml ; 3.94e-05 mol/l
		Class 📀	Moderately soluble
	INSOLU		Pharmacokinetics
SMILES Oc1ccc(cc1)c1cc	(=0)c2c(o1)cc(cc20)0	GI absorption 📀	High
	hysicochemical Properties	BBB permeant 🧐	No
Formula	C15H10O5	P-gp substrate 📀	No
Molecular weight	270.24 g/mol	CYP1A2 inhibitor 📀	Yes
Num. heavy atoms	20	CYP2C19 inhibitor 🧐	No
Num. arom. heavy atoms	16	CYP2C9 inhibitor 📀	No
Fraction Csp3	0.00	CYP2D6 inhibitor 📀	Yes
Num. rotatable bonds	1	CYP3A4 inhibitor 📀	Yes
Num. H-bond acceptors	5	Log K _p (skin permeation) 📀	-5.80 cm/s
Num. H-bond donors	3		Druglikeness
Molar Refractivity	73.99	Lipinski 📀	Yes; 0 violation
TPSA 🤨	90.90 Ų	Ghose 📀	Yes
	Lipophilicity	Veber 📀	Yes
Log P _{o/w} (iLOGP) 📀	1.89	Egan 🔞	Yes
Log P _{o/w} (XLOGP3) 📀	3.02	Muegge 📀	Yes
Log P _{o/w} (WLOGP) 😣	2.58	Bioavailability Score 📀	0.55
Log P _{o/w} (MLOGP) 🔞	0.52		Medicinal Chemistry
Log P _{o/w} (SILICOS-IT) 🥹	2.52	PAINS 🤨	0 alert
Consensus Log P _{o/w} (9)	2.11	Brenk 🤨	0 alert
	a	Leadlikeness 🛞	Yes
		Synthetic accessibility 🤨	2.96

Fig 20: Analysis of Drug Likeness Property of Molecule 11

ISSN No:-2456-2165

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

C. Hesperetin

Hesperetin, or 3,5,7-trihydroxy-4-methoxyflavonone, is a flavonoid that is frequently present in citrus fruits, such as tangerines, oranges, and grapefruits. Citrus aurantinum, Citrus sinensis, and Citrus limon are the principal sources of it. Fruit juices come in a variety of forms, and orange and grapefruit drinks are particularly high in HSP. It is a naturally occurring bioactive substance that is a member of the flavanone class of flavonoids.(24)The 40-methoxy derivative of the flavanone eriodictvol is known as HSP. HSP has the chemical formula C₁₆H₁₄O₆. It has a topological polar surface area of 96.2 \times 2, one covalently bound unit quantity, 22 heavy atom counts, and no formal charge. HSP has a precise mass of 302.079, while its molecular weight is 302.28 g/mol. Methyl eriodyctiol, or HSP, is an aglycone derived from hesperidin that is bound to rutinose in hesperidin. Phloroglucinol and HSP acid can be hydrolyzed alkaline together to generate HSP. The heterocyclic and aromatic ring contains three hydroxyl groups that are accessible and

involved in a number of biological processes.(25) Through the stimulation of apoptosis, hesperetin demonstrated anticancer effectiveness against A431 skin carcinoma cancer cell lines, according to the current study. It was discovered that hesperetin caused Notch1 expression in carcinoid cells, which stops the growth of tumour cells, and triggered cell cycle arrest in the G1-phase in human breast cancer (MCF-7) cells. Hesperetin used death receptors, mitochondrial pathways, and cell cycle arrest to cause human cervical cancer cells to undergo apoptosis.(26) Hesperetin increases intracellular ROS levels, which further activates the mitochondrial pathway, inhibiting the growth of stomach cancer cells and inducing cell death.8 With an IC50 of 10 μ g/ml, apigenin and hesperidin have strong cytotoxic effects in the MCF7 cell line while exhibiting modest toxicity. There are few scientific reports of hesperidin's negative effects, especially in pregnant women, making it a safe bioflavonoid.(27)

Molecule 1			
# ⊙ ⊘			Water Solubility
	LIPO	Log S (ESOL) 📀	-3.62
		Solubility	7.19e-02 mg/ml ; 2.38e-04 mol/l
	FLEX SIZE	Class 😣	Soluble
		Log S (Ali) 😣	-4.27
но		Solubility	1.62e-02 mg/ml ; 5.37e-05 mol/l
	C#	Class 😣	Moderately soluble
P	INSATU	Log S (SILICOS-IT) 📀	-3.53
сн,		Solubility	8.84e-02 mg/ml ; 2.92e-04 mol/l
		Class 🐵	Soluble
	INSOLU		Pharmacokinetics
SMILES COc1ccc(cc10)C	100(=0)c2c(01)cc(cc20)0	GI absorption 😣	High
	ysicochemical Properties	BBB permeant 📀	No
Formula	C16H14O6	P-gp substrate 📀	Yes
Molecular weight	302.28 g/mol	CYP1A2 inhibitor 📀	Yes
Num. heavy atoms	22	CYP2C19 inhibitor 📀	No
Num. arom. heavy atoms	12	CYP2C9 inhibitor 🧐	No
Fraction Csp3	0.19	CYP2D6 inhibitor 📀	No
Num. rotatable bonds	2	CYP3A4 inhibitor 🧐	Yes
Num. H-bond acceptors	6	Log K _p (skin permeation) 📀	-6.30 cm/s
Num. H-bond donors	3		Druglikeness
Molar Refractivity	78.06	Lipinski 🧐	Yes; 0 violation
TPSA 🛞	96.22 Å ^z	Ghose 🧐	Yes
	Lipophilicity	Veber 🔞	Yes
Log P _{o/w} (iLOGP) 🥯	2.24	Egan 🔞	Yes
Log P _{o/w} (XLOGP3) 📀	2.60	Muegge 📀	Yes
Log P _{o/w} (WLOGP) 😣	2.19	Bioavailability Score 😣	0.55
Log P _{o/w} (MLOGP) 📀	0.41		Medicinal Chemistry
Log P _{o/w} (SILICOS-IT) 🧐	2.08	PAINS 0	0 alert
Consensus Log Poly 😣	1.91	Brenk 🥺	0 alert
67 W W		Leadlikeness 📀	Yes
		Synthetic accessibility 🧐	3.22

Fig 21: Analysis of Drug Likeness Property of Molecule 12

D. Quercetin

Quercetin (3,3',4',5,7-pentahydroxyflavone) is a naturally occurring flavonoid found in various plants, fruits, and vegetables, including broccoli, buckwheat, and onions, as well as in large amounts as glycoside. As a commercial dietary supplement, it has been added to functional meals and may help prevent or treat a number of illnesses, including cancer.10 With an IC₅₀ value of 40 g/ml, the flavonoids quercetin and rutin found in Cissus quadrangularis Linn.

fractions have strong anticancer properties against breast cancer cells (MCF7).(28)

In alcohol, quercetin is somewhat soluble, but it is insoluble in water. Because there is very little absorption of quercetin glycosides in the small intestine, the microflora in the lower intestines hydrolyzes the glycosides to produce quercetin and sugar, which is then absorbed into the enterohepatic system. When quercetin is used in conjunction with other forms of treatment for esophageal cancer, it seems

ISSN No:-2456-2165

to work better.(29) Because quercetin is lipophilic, it easily crosses cell membranes and has a variety of pleiotropic effects on intracellular pathways that are involved in chemoprevention (such as apoptosis, the cell cycle arrest, detoxification, cell invasion, and angiogenesis). Though, quercetin's limited solubility in water, quick metabolism, rapid bodily clearance, and enzymatic degradation significantly impede its practical applicability as an anticancer medication. The usage of quercetin has been limited since it has been demonstrated to have harmful effects on normal human cell lines in vitro.(30)

According to recent research, quercetin can both prevent and treat cancer by preventing cancer cells from growing. In order to lessen the negative effects of therapy, quercetin at lower doses might be used in conjunction with other therapeutic drugs. Therefore, in cases of oestrogen receptorpositive breast cancer, quercetin functions as a possible antibreast cancer agent.(31). A nontoxic dosage of quercetin may somewhat mitigate the toxic side effects of doxorubicin while enhancing its chemotherapeutic activity against human breast cancer cells. Thus, quercetin may be utilised in combination with Dox as new moiety for treating breast cancer.(32) Its molecular weight was determined to be 302.24 g/mol, with 22 heavy atoms and 16 aromatic heavy atoms, in that order. It lacks BBB penetrating properties and has a high G.I. absorption rate. It has five H-bond donors and seven H-bond acceptors. Given that it complies with all Lipinski criteria, its drug resemblance is high. Thus, it is a formulation that may be taken orally. Because quercetin is a lipophilic substance, eating fat increases its bioavailability.

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

Molecule 1			
Ħ ⊕ \` <i>Q</i>	LIPO		Water Solubility
	LIPO	Log S (ESOL) 📀	-3.16
		Solubility	2.11e-01 mg/ml ; 6.98e-04 mol/l
	FLEX	Class 🥹	Soluble
но		Log S (Ali) 🧐	-3.91
I I		Solubility	3.74e-02 mg/ml ; 1.24e-04 mol/l
	ОН	Class 🥹	Soluble
но	INSATU	Log S (SILICOS-IT) 📀	-3.24
		Solubility	1.73e-01 mg/ml ; 5.73e-04 mol/l
		Class 📀	Soluble
	INSOLU		Pharmacokinetics
SMILES Oc1cc(O)c2c(c1)c	pc(c(c2=0)0)c1ccc(c(c1)0)0	GI absorption 📀	High
	hysicochemical Properties	BBB permeant 😣	No
Formula	C15H10O7	P-gp substrate 📀	No
Molecular weight	302.24 g/mol	CYP1A2 inhibitor 📀	Yes
Num. heavy atoms	22	CYP2C19 inhibitor 📀	No
Num. arom. heavy atoms	16	CYP2C9 inhibitor 📀	No
Fraction Csp3	0.00	CYP2D6 inhibitor 📀	Yes
Num. rotatable bonds	1	CYP3A4 inhibitor 📀	Yes
Num. H-bond acceptors	7	Log K _p (skin permeation) 🤫	-7.05 cm/s
Num. H-bond donors	5		Druglikeness
Molar Refractivity	78.03	Lipinski 😗	Yes; 0 violation
TPSA 🔞	131.36 Ų	Ghose 📀	Yes
	Lipophilicity	Veber 📀	Yes
Log P _{o/w} (iLOGP) 😢	1.63	Egan 📀	Yes
Log P _{o/w} (XLOGP3) 📀	1.54	Muegge 🤨	Yes
Log P _{o/w} (WLOGP) 🥹	1.99	Bioavailability Score 🥹	0.55
Log P _{o/w} (MLOGP) 😣	-0.56		Medicinal Chemistry
Log P _{o/w} (SILICOS-IT) 📀	1.54	PAINS 😣	1 alert: catechol_A 9
Consensus Log Poly 0	1.23	Brenk 🤨	1 alert: catechol ⁽²⁾
5 WW		Leadlikeness ⁽²⁾	Yes
		Synthetic accessibility 📀	3.23

Fig 22: Analysis of Drug Likeness Property of Molecule 13

ISSN No:-2456-2165

E. Pterocarpans

Pterocarpans are naturally occurring substances with an ether bond and a tetracyclic ring structure formed from the fundamental isoflavonoid skeleton. The most effective of these compounds, 2,3,9-trimethoxypterocarpan, was shown to exhibit cytotoxic action against a panel of five tumour cell lines. Platymiscium floribundum, a Brazilian tree, is the source of these chemicals. Compared to the antineoplastic drugs doxorubicin and etoposide, it has 1000 times more activity. In three different breast cancer cell lines, 2,3,9trimethoxypterocarpan at 8 mM demonstrated effectiveness regardless of the cells' aggressive characteristics.(33) It has been demonstrated that Lespedeza bicolor inhibits the growth of cancer cells. Pterocarpans isolated from the roots of L. bicolar showed strong cytotoxic effects, such as inducing

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

apoptosis in Jurkat cells, and shown an antiproliferative activity against cancer cell lines.(34) It has been claimed that tokinensine A and B include cystisine-type alkaloids, which have been investigated for cytotoxicity against human breast cancer cells and feature a skeleton linked to the pterocarpan. They came from an extract of the traditional Chinese medicinal Sophora tonkinensis.(35) Indigocarpan's strong antioxidant activity suggests that it may have a function in preventing the development of cancer by shielding cells from oxidative stress(36). The current work highlights the significance of pterocarpans as a newly discovered family of potentially effective anticancer compounds. Pterocarpans block DNA synthesis and induce death in HL-60, hence showing an antiproliferative action(37).

Molecule 1			
# ⊕ ◯ ₽			Water Solubility
	LIPO	Log S (ESOL) 🔞	-3.74
		Solubility	4.11e-02 mg/ml ; 1.83e-04 mol/l
	FLEX	Class 📀	Soluble
		Log S (Ali) 😣	-3.21
		Solubility	1.39e-01 mg/ml ; 6.20e-04 mol/l
		Class 🥹	Soluble
	INSATU	Log S (SILICOS-IT) 📀	-4.76
		Solubility	3.86e-03 mg/ml ; 1.72e-05 mol/l
		Class 🔞	Moderately soluble
	INSOLU		Pharmacokinetics
SMILES c1ccc2c(c1)C1Oc	3c(C1CO2)cccc3	GI absorption 🥹	High
Physicochemical Properties		BBB permeant 🛞	Yes
Formula	C15H12O2	P-gp substrate 📀	Yes
Molecular weight	224.25 g/mol	CYP1A2 inhibitor 🛞	Yes
Num. heavy atoms	17	CYP2C19 inhibitor 📀	No
Num. arom. heavy atoms	12	CYP2C9 inhibitor 🥹	No
Fraction Csp3	0.20	CYP2D6 inhibitor 🛞	Yes
Num. rotatable bonds	0	CYP3A4 inhibitor 📀	No
Num. H-bond acceptors	2	Log K _p (skin permeation) 🤨	-5.43 cm/s
Num. H-bond donors	0		Druglikeness
Molar Refractivity	64.65	Lipinski 🤨	Yes; 0 violation
TPSA 🤨	18.46 Ų	Ghose 📀	Yes
	Lipophilicity	Veber 🔞	Yes
Log P _{o/w} (iLOGP) 📀	2.51	Egan 🔞	Yes
Log P _{o/w} (XLOGP3) 🥹	3.15	Muegge 🤨	Yes
Log P _{o/w} (WLOGP) 🥹	2.97	Bioavailability Score 📀	0.55
Log P _{o/w} (MLOGP) 📀	2.81		Medicinal Chemistry
Log Poly (SILICOS-IT)	3.28	PAINS 🧐	0 alert
Consensus Log Poly 0	2.95	Brenk 📀	0 alert
Consensus Log r O/W	2.00	Leadlikeness 📀	No; 1 violation: MW<250
		Synthetic accessibility 📀	3.29

Fig 23. Analysis of Drug Likeness of Molecule 14

VII. CONCLUSION

In this review, we analysed the drug-like qualities of flavonoids and isoflavonoids as possible anticancer agents, and we chose various molecules with superior physiochemical characteristics. Additionally, by reading through various literature, we saw improved interactions between the flavonoid scaffold and receptors. The structures of all derivatives were analysed using SwissADME and Chemdraw tools, respectively. Furthermore, we have studied the structures of flavonoids and flavanols and calculated the total energy, or stability, using energy minimization. Flavonoids are highly suggested as anticancer medications for different stages of cancer because of their exceptional stability.

ISSN No:-2456-2165

REFERENCES

- [1]. Rampogu S, Gajula RG, Lee KW. A comprehensive review on chemotherapeutic potential of galangin. Biomedicine & Pharmacotherapy. 2021;141:111808.
- [2]. Zhong H, Xiao M, Zarkovic K, Zhu M, Sa R, Lu J, et al. Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: A novel link between oxidative stress and cancer. Free Radical Biology and Medicine. 2017;102:67-76.
- [3]. Wu M, Luo Q, Nie R, Yang X, Tang Z, Chen H. Potential implications of polyphenols on aging considering oxidative stress, inflammation, autophagy, and gut microbiota. Critical reviews in food science and nutrition. 2021;61(13):2175-93.
- [4]. Abotaleb M, Samuel SM, Varghese E, Varghese S, Kubatka P, Liskova A, Büsselberg D. Flavonoids in cancer and apoptosis. Cancers. 2018;11(1):28.
- [5]. Liskova A, Koklesova L, Samec M, Smejkal K, Samuel SM, Varghese E, et al. Flavonoids in cancer metastasis. Cancers. 2020;12(6):1498.
- [6]. Manzoor A, Dar IH, Bhat SA, Ahmad S. Flavonoids: health benefits and their potential use in food systems. Functional food products and sustainable health. 2020:235-56.
- [7]. Hossain MM, Mahmood S, Tanmy TT. The beneficial effects of green tea on human health: An updated review. Int J Herb Med. 2020;63:63-73.
- [8]. Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. Flavonoids as anticancer agents. Nutrients. 2020;12(2):457.
- [9]. Dorta DJ, Pigoso AA, Mingatto FE, Rodrigues T, Prado IM, Helena AF, et al. The interaction of flavonoids with mitochondria: effects on energetic processes. Chemico-biological interactions. 2005;152(2-3):67-78.
- [10]. Vegliante R, Di Leo L, Ciccarone F, Ciriolo MR. Hints on ATGL implications in cancer: beyond bioenergetic clues. Cell death & disease. 2018;9(3):316.
- [11]. Lu S, Wang Y. Nonmetabolic functions of metabolic enzymes in cancer development. Cancer Communications. 2018;38:1-7.
- [12]. Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Progress in lipid research. 2013;52(4):585-9.
- [13]. Weinberg F, Ramnath N, Nagrath D. Reactive oxygen species in the tumor microenvironment: an overview. Cancers. 2019;11(8):1191.
- [14]. Kiebish MA, Han X, Cheng H, Chuang JH, Seyfried TN. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. Journal of lipid research. 2008;49(12):2545-56.
- [15]. Bock FJ, Tait SW. Mitochondria as multifaceted regulators of cell death. Nature reviews Molecular cell biology. 2020;21(2):85-100.

[16]. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise. International journal of oncology. 2007;30(1):233-45.

https://doi.org/10.38124/ijisrt/IJISRT24APR2622

- [17]. Yan X, Qi M, Li P, Zhan Y, Shao H. Apigenin in cancer therapy: Anti-cancer effects and mechanisms of action. Cell & bioscience. 2017;7:1-16.
- [18]. Noori SD, Kadhi MS, Najm MA, Oudah KH, Qasim QA, Al-Salman H. In-vitro evaluation of anticancer activity of natural flavonoids, apigenin and hesperidin. Materials Today: Proceedings. 2022;60:1840-3.
- [19]. Tuli HS, Tuorkey MJ, Thakral F, Sak K, Kumar M, Sharma AK, et al. Molecular mechanisms of action of genistein in cancer: Recent advances. Frontiers in Pharmacology. 2019;10:489844.
- [20]. Li Q-S, Li C-Y, Li Z-L, Zhu H-L. Genistein and its synthetic analogs as anticancer agents. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2012;12(3):271-81.
- [21]. Jeune ML, Kumi-Diaka J, Brown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. Journal of medicinal food. 2005;8(4):469-75.
- [22]. Lee J-Y, Kim HS, Song Y-S. Genistein as a potential anticancer agent against ovarian cancer. Journal of Traditional and Complementary Medicine. 2012;2(2):96-104.
- [23]. Chae H-S, Xu R, Won J-Y, Chin Y-W, Yim H. Molecular targets of genistein and its related flavonoids to exert anticancer effects. International Journal of Molecular Sciences. 2019;20(10):2420.
- [24]. Zhang J, Song J, Wu D, Wang J, Dong W. Hesperetin induces the apoptosis of hepatocellular carcinoma cells via mitochondrial pathway mediated by the increased intracellular reactive oxygen species, ATP and calcium. Medical Oncology. 2015;32:1-11.
- [25]. Sohel M, Sultana H, Sultana T, Al Amin M, Aktar S, Ali MC, et al. Chemotherapeutic potential of hesperetin for cancer treatment, with mechanistic insights: A comprehensive review. Heliyon. 2022;8(1).
- [26]. Zhang J, Wu D, Vikash, Song J, Wang J, Yi J, Dong W. Hesperetin induces the apoptosis of gastric cancer cells via activating mitochondrial pathway by increasing reactive oxygen species. Digestive diseases and sciences. 2015;60:2985-95.
- [27]. Tang S-M, Deng X-T, Zhou J, Li Q-P, Ge X-X, Miao L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomedicine & Pharmacotherapy. 2020;121:109604.
- [28]. Vijayalakshmi A, Kumar P, Sakthi Priyadarsini S, Meenaxshi C. In vitro antioxidant and anticancer activity of flavonoid fraction from the aerial parts of Cissus quadrangularis Linn. against human breast carcinoma cell lines. Journal of Chemistry. 2013;2013.
- [29]. Davoodvandi A, Shabani Varkani M, Clark CC, Jafarnejad S. Quercetin as an anticancer agent: Focus on esophageal cancer. Journal of Food Biochemistry. 2020;44(9):e13374.

ISSN No:-2456-2165

- [30]. Massi A, Bortolini O, Ragno D, Bernardi T, Sacchetti G, Tacchini M, De Risi C. Research progress in the modification of quercetin leading to anticancer agents. Molecules. 2017;22(8):1270.
- [31]. Ranganathan S, Halagowder D, Sivasithambaram ND. Quercetin suppresses twist to induce apoptosis in MCF-7 breast cancer cells. PloS one. 2015;10(10):e0141370.
- [32]. Li ShiZheng LS, Yuan Song YS, Zhao Qian ZQ, Wang Bo WB, Wang XiuYan WX, Li Kun LK. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it. 2018.
- [33]. Thuy NTT, Lee J-E, Yoo HM, Cho N. Antiproliferative pterocarpans and coumestans from Lespedeza bicolor. Journal of natural products. 2019;82(11):3025-32.
- [34]. Peng T-T, Sun X-R, Liu R-H, Hua L-X, Cheng D-P, Mao B, Li X-N. Cytisine-Pterocarpan Derived Compounds: Biomimetic Synthesis and Apoptosis-Inducing Activity in Human Breast Cancer Cells. Molecules. 2018;23(12):3059.
- [35]. Mahajan P, Gnana Oli R, Jachak SM, Bharate SB, Chaudhuri B. Antioxidant and antiproliferative activity of indigocarpan, a pterocarpan from Indigofera aspalathoides. Journal of Pharmacy and Pharmacology. 2016;68(10):1331-9.
- [36]. Militão GC, Dantas IN, Pessoa C, Falcão MJC, Silveira ER, Lima MAS, et al. Induction of apoptosis by pterocarpans from Platymiscium floribundum in HL-60 human leukemia cells. Life sciences. 2006;78(20):2409-17.
- [37]. Kuete V, Sandjo LP, Djeussi DE, Zeino M, Kwamou GM, Ngadjui B, Efferth T. Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells. Investigational New Drugs. 2014;32:1053-62.